Skip to main content
58°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alvotech
< Previous
1
2
3
Next >
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
February 27, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Settlement of Alvotech Private Share Placement Completed
February 10, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
February 09, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
February 06, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
January 24, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Completes $137 Million Private Share Placement
January 23, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
January 13, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
January 11, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
TEVA
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
December 22, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
TEVA
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Completes $59.7 Million Private Placement
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
December 08, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
December 07, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Changes to its Leadership Team
December 01, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Secures Financing Facilities of Approximately $136 Million
November 16, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
November 16, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
November 14, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
November 10, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
October 27, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November
October 26, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
October 19, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan
October 17, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Appoints Sarah Tanksley as Chief Quality Officer
October 11, 2022
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16
June 15, 2022
From
Alvotech
Via
Business Wire
STADA and Alvotech broaden European patients’ options by launching Hukyndra® high-concentration, citrate-free adalimumab
June 09, 2022
From
Alvotech
Via
Business Wire
AVT02, Alvotech’s Biosimilar to High Concentration Formulation of Adalimumab (Humira®) Approved for Use in European Union
December 15, 2021
From
Alvotech
Via
Business Wire
Alvotech Beats Back AbbVie’s Trade Secrets Lawsuit
October 07, 2021
From
Alvotech
Via
Business Wire
Alvotech Provides Update on FDA Action Regarding AVT02, Proposed High-Concentration Biosimilar to Humira® (adalimumab)
September 20, 2021
From
Alvotech
Via
Business Wire
Alvotech Welcomes Positive CHMP Opinion for AVT02, a Proposed Biosimilar to Humira®
September 17, 2021
From
Alvotech
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.